Infliximab and biosimilar Market Report

Global Infliximab and biosimilar Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 11, 2022
  • PAGES：223
  • REPORT CODE：GMM811698
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Infliximab and biosimilar market report explains the definition, types, applications, major countries, and major players of the Infliximab and biosimilar market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Pfizer

    • Merck and Co

    • Janssen Biotech

    By Type:

    • Infliximab

    • infliximab-dyyb

    • infliximab-abda

    By End-User:

    • Crohn's Disease

    • Pediatric Crohn's Disease

    • Ulcerative Colitis

    • Rheumatoid Arthritis

    • Ankylosing Spondylitis

    • Psoriatic Arthritis

    • Plaque Psoriasis

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Infliximab and biosimilar Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Infliximab and biosimilar Outlook to 2028- Original Forecasts

    • 2.2 Infliximab and biosimilar Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Infliximab and biosimilar Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Infliximab and biosimilar Market- Recent Developments

    • 6.1 Infliximab and biosimilar Market News and Developments

    • 6.2 Infliximab and biosimilar Market Deals Landscape

    7 Infliximab and biosimilar Raw Materials and Cost Structure Analysis

    • 7.1 Infliximab and biosimilar Key Raw Materials

    • 7.2 Infliximab and biosimilar Price Trend of Key Raw Materials

    • 7.3 Infliximab and biosimilar Key Suppliers of Raw Materials

    • 7.4 Infliximab and biosimilar Market Concentration Rate of Raw Materials

    • 7.5 Infliximab and biosimilar Cost Structure Analysis

      • 7.5.1 Infliximab and biosimilar Raw Materials Analysis

      • 7.5.2 Infliximab and biosimilar Labor Cost Analysis

      • 7.5.3 Infliximab and biosimilar Manufacturing Expenses Analysis

    8 Global Infliximab and biosimilar Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Infliximab and biosimilar Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Infliximab and biosimilar Export by Region (Top 10 Countries) (2017-2028)

    9 Global Infliximab and biosimilar Market Outlook by Types and Applications to 2022

    • 9.1 Global Infliximab and biosimilar Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Infliximab Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global infliximab-dyyb Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global infliximab-abda Consumption and Growth Rate (2017-2022)

    • 9.2 Global Infliximab and biosimilar Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Crohn's Disease Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Pediatric Crohn's Disease Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Ulcerative Colitis Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Rheumatoid Arthritis Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Ankylosing Spondylitis Consumption and Growth Rate (2017-2022)

      • 9.2.6 Global Psoriatic Arthritis Consumption and Growth Rate (2017-2022)

      • 9.2.7 Global Plaque Psoriasis Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Infliximab and biosimilar Market Analysis and Outlook till 2022

    • 10.1 Global Infliximab and biosimilar Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Infliximab and biosimilar Consumption (2017-2022)

      • 10.2.2 Canada Infliximab and biosimilar Consumption (2017-2022)

      • 10.2.3 Mexico Infliximab and biosimilar Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.2 UK Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.3 Spain Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.4 Belgium Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.5 France Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.6 Italy Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.7 Denmark Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.8 Finland Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.9 Norway Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.10 Sweden Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.11 Poland Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.12 Russia Infliximab and biosimilar Consumption (2017-2022)

      • 10.3.13 Turkey Infliximab and biosimilar Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.2 Japan Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.3 India Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.4 South Korea Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.5 Pakistan Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.6 Bangladesh Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.7 Indonesia Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.8 Thailand Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.9 Singapore Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.10 Malaysia Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.11 Philippines Infliximab and biosimilar Consumption (2017-2022)

      • 10.4.12 Vietnam Infliximab and biosimilar Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Infliximab and biosimilar Consumption (2017-2022)

      • 10.5.2 Colombia Infliximab and biosimilar Consumption (2017-2022)

      • 10.5.3 Chile Infliximab and biosimilar Consumption (2017-2022)

      • 10.5.4 Argentina Infliximab and biosimilar Consumption (2017-2022)

      • 10.5.5 Venezuela Infliximab and biosimilar Consumption (2017-2022)

      • 10.5.6 Peru Infliximab and biosimilar Consumption (2017-2022)

      • 10.5.7 Puerto Rico Infliximab and biosimilar Consumption (2017-2022)

      • 10.5.8 Ecuador Infliximab and biosimilar Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Infliximab and biosimilar Consumption (2017-2022)

      • 10.6.2 Kuwait Infliximab and biosimilar Consumption (2017-2022)

      • 10.6.3 Oman Infliximab and biosimilar Consumption (2017-2022)

      • 10.6.4 Qatar Infliximab and biosimilar Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Infliximab and biosimilar Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Infliximab and biosimilar Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Infliximab and biosimilar Consumption (2017-2022)

      • 10.7.2 South Africa Infliximab and biosimilar Consumption (2017-2022)

      • 10.7.3 Egypt Infliximab and biosimilar Consumption (2017-2022)

      • 10.7.4 Algeria Infliximab and biosimilar Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Infliximab and biosimilar Consumption (2017-2022)

      • 10.8.2 New Zealand Infliximab and biosimilar Consumption (2017-2022)

    11 Global Infliximab and biosimilar Competitive Analysis

    • 11.1 Pfizer

      • 11.1.1 Pfizer Company Details

      • 11.1.2 Pfizer Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Pfizer Infliximab and biosimilar Main Business and Markets Served

      • 11.1.4 Pfizer Infliximab and biosimilar Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Merck and Co

      • 11.2.1 Merck and Co Company Details

      • 11.2.2 Merck and Co Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Merck and Co Infliximab and biosimilar Main Business and Markets Served

      • 11.2.4 Merck and Co Infliximab and biosimilar Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Janssen Biotech

      • 11.3.1 Janssen Biotech Company Details

      • 11.3.2 Janssen Biotech Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Janssen Biotech Infliximab and biosimilar Main Business and Markets Served

      • 11.3.4 Janssen Biotech Infliximab and biosimilar Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    12 Global Infliximab and biosimilar Market Outlook by Types and Applications to 2028

    • 12.1 Global Infliximab and biosimilar Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Infliximab Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global infliximab-dyyb Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global infliximab-abda Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Infliximab and biosimilar Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Pediatric Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Rheumatoid Arthritis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.5 Global Ankylosing Spondylitis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.6 Global Psoriatic Arthritis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.7 Global Plaque Psoriasis Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Infliximab and biosimilar Market Analysis and Outlook to 2028

    • 13.1 Global Infliximab and biosimilar Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.2.2 Canada Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Infliximab and biosimilar Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.2 UK Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.3 Spain Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.5 France Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.6 Italy Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.8 Finland Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.9 Norway Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.11 Poland Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.12 Russia Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Infliximab and biosimilar Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.2 Japan Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.3 India Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Infliximab and biosimilar Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.5.3 Chile Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.5.6 Peru Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Infliximab and biosimilar Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.6.3 Oman Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Infliximab and biosimilar Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Infliximab and biosimilar Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Infliximab and biosimilar Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Infliximab and biosimilar Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Infliximab and biosimilar

    • Figure of Infliximab and biosimilar Picture

    • Table Global Infliximab and biosimilar Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Infliximab and biosimilar Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Infliximab Consumption and Growth Rate (2017-2022)

    • Figure Global infliximab-dyyb Consumption and Growth Rate (2017-2022)

    • Figure Global infliximab-abda Consumption and Growth Rate (2017-2022)

    • Figure Global Crohn's Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Pediatric Crohn's Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Ulcerative Colitis Consumption and Growth Rate (2017-2022)

    • Figure Global Rheumatoid Arthritis Consumption and Growth Rate (2017-2022)

    • Figure Global Ankylosing Spondylitis Consumption and Growth Rate (2017-2022)

    • Figure Global Psoriatic Arthritis Consumption and Growth Rate (2017-2022)

    • Figure Global Plaque Psoriasis Consumption and Growth Rate (2017-2022)

    • Figure Global Infliximab and biosimilar Consumption by Country (2017-2022)

    • Table North America Infliximab and biosimilar Consumption by Country (2017-2022)

    • Figure United States Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Canada Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Mexico Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Table Europe Infliximab and biosimilar Consumption by Country (2017-2022)

    • Figure Germany Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure UK Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Spain Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Belgium Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure France Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Italy Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Denmark Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Finland Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Norway Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Sweden Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Poland Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Russia Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Turkey Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Table APAC Infliximab and biosimilar Consumption by Country (2017-2022)

    • Figure China Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Japan Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure India Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure South Korea Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Thailand Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Singapore Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Philippines Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Table South America Infliximab and biosimilar Consumption by Country (2017-2022)

    • Figure Brazil Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Colombia Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Chile Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Argentina Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Peru Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Table GCC Infliximab and biosimilar Consumption by Country (2017-2022)

    • Figure Bahrain Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Oman Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Qatar Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Table Africa Infliximab and biosimilar Consumption by Country (2017-2022)

    • Figure Nigeria Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure South Africa Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Egypt Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Algeria Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Table Oceania Infliximab and biosimilar Consumption by Country (2017-2022)

    • Figure Australia Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Infliximab and biosimilar Consumption and Growth Rate (2017-2022)

    • Table Pfizer Company Details

    • Table Pfizer Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Infliximab and biosimilar Main Business and Markets Served

    • Table Pfizer Infliximab and biosimilar Product Portfolio

    • Table Merck and Co Company Details

    • Table Merck and Co Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck and Co Infliximab and biosimilar Main Business and Markets Served

    • Table Merck and Co Infliximab and biosimilar Product Portfolio

    • Table Janssen Biotech Company Details

    • Table Janssen Biotech Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Janssen Biotech Infliximab and biosimilar Main Business and Markets Served

    • Table Janssen Biotech Infliximab and biosimilar Product Portfolio

    • Figure Global Infliximab Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global infliximab-dyyb Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global infliximab-abda Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pediatric Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Rheumatoid Arthritis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ankylosing Spondylitis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Psoriatic Arthritis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Plaque Psoriasis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Infliximab and biosimilar Consumption Forecast by Country (2022-2028)

    • Table North America Infliximab and biosimilar Consumption Forecast by Country (2022-2028)

    • Figure United States Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Infliximab and biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Germany Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Infliximab and biosimilar Consumption Forecast by Country (2022-2028)

    • Figure China Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Infliximab and biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Brazil Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Infliximab and biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Infliximab and biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Infliximab and biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Australia Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US